Drs. Ballantyne, Haffner, Koenig, Nesto, Ridker & Rifai composed the CRP health.com Editorial Board

Click here to visit our General Public Section

Welcome

Online Presentations

What is C-Reactive Protein (CRP) ? - Guidelines - Clinical Trials - Discussion Forum - Editorial Board - Supporter - About

Editorial Board

The Editorial Board of CRPhealth.com is an independent committee whose mission is to ensure the scientific quality of the online conferences and other medical content on the website. Our tasks are to recommend presentations for recording, based on their importance and relevance to physicians and patients; as well as supervising the addition of important medical publications and resources about CRP on the website.

The Editorial Board firmly believes that the success of CRPhealth.com depends upon the participation of its members. We want to hear your ideas; the success of CRPhealth.com relies on it.

Contact us : editorialboard@CRPhealth.com

Editorial Board Disclosure

Members of the Editorial Board of CRPhealth.com receive honoraria for their efforts in reviewing and providing content for this site. Dr. Ballantyne discloses grant/research support from Abbott, ActivBiotics, Gene Logic, GlaxoSmithKline, Integrated Therapeutics, Merck, Pfizer, Schering-Plough, Sanofi-Synthelabo, and Takeda; consultant for Abbott, AstraZeneca, Atherogenics, GlaxoSmithKline, Merck, Merck Schering-Plough, Novartis, Pfizer, Reliant, Schering-Plough, Sanofi-Synthelabo, and Takeda; speakers’ bureau for AstraZeneca, Merck, Pfizer, Reliant, and Schering-Plough. Dr. Jialal discloses advisory board for marketing purposes for Merck; advisory board for scientific information for Sankyo; grant recipient/research support from American Diabetes Association and Juvenile Diabetes Association; promotional speakers’ bureau for Merck. Dr. Katz discloses no relevant financial relationship with any commercial interest. Dr. Koenig discloses advisory board for scientific information for GlaxoSmithKline, Merck-Serono, and Roche; consultant for clinical trial design for Anthera Pharmaceuticals, GlaxoSmithKline, Merck-Serono, and Roche; grant recipient/research support from Dade-Behring and Roche; promotional speakers’ bureau for AstraZeneca, GlaxoSmithKline, Merck, and Novartis. Dr. Mainardi discloses no relevant financial relationship with any commercial interest. Dr. Ridker discloses advisory board for scientific information for AstraZeneca, Dade-Behring, Merck, and Schering-Plough; consultant for clinical trial design for AstraZeneca, Novartis, and Sanofi-Aventis; grant recipient/research support for NHLBI, NCI, Reynolds Foundation, Leducq Foundation, Abbott, AstraZeneca, Novartis, and Sanofi-Aventis; intellectual property/patents, Dr. Ridker is listed as a co-inventor on patents held by the Brigham and Women’s Hospital that relate to the use of inflammatory biomarkers in cardiovascular disease.

Editorial Board Members

Apr 5

	Christie M. Ballantyne, MD Associate Chief and Professor Director, Center for Cardiovascular Disease Prevention Director, The Maria and Alando J. Ballantyne, M.D. Artherosclerosis Clinical Research Laboratory Director, Clinical Activities Co-Director, Lipid Metabolism and Atherosclerosis Clinic Section of Atherosclerosis and Vascular Medicine Department of Medicine Baylor College of Medicine Houston, TX Christie M. Ballantyne, M.D., is Director of the Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart Center; Chief of the Section of Atherosclerosis and Vascular Medicine, Department of Medicine, Baylor College of Medicine; Director of the Maria and Alando J. Ballantyne, M.D., Atherosclerosis Laboratory; Professor of Medicine with a joint appointment in Pediatrics, Baylor College of Medicine; and Co-Director, Lipid Metabolism and Atherosclerosis Clinic, The Methodist Hospital, Houston, Texas. He received his Doctor of Medicine from Baylor College of Medicine, and his postgraduate training included an internal medicine residency at The University of Texas Southwestern Medical School, Dallas, Texas, a cardiology fellowship at Baylor College of Medicine, and an American Heart Association/Bugher Foundation Fellowship at the Howard Hughes Medical Institute and Institute for Molecular Genetics at Baylor. Dr. Ballantyne is a Fellow of the American Association for the Advancement of Science, member of the American Society for Clinical Investigation, Fellow of the American College of Cardiology, and Fellow of the American College of Physicians. He previously served as governor of the Texas Chapter of the American College of Cardiology and president of the Houston Chapter of the American Heart Association. Dr. Ballantyne has been the recipient of numerous study grants, including an American Heart Association Established Investigator Award and several NIH grants to study leukocyte–endothelial adhesion molecules and novel biomarkers for atherosclerosis. He has been a member of numerous steering committees for multicenter trials, including the Atherosclerosis Risk in Communities (ARIC) study, Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE IT), A Study to Evaluate the Effect of Rosuvastatin on Intravascular Ultrasound-Derived Coronary Atheroma Burden (ASTEROID), National Cholesterol Education Program Evaluation Project Utilizing Novel E-Technology II (NEPTUNE II), and Effect of Niacin ER/Lovastatin on Peak Walking Time and Claudication Onset Time in Patients With Intermittent Claudication (ICPOP), and has also participated as a member of several Data and Safety Monitoring Boards. Dr. Ballantyne is Editorial Director for www.lipidsonline.org. He has published extensively and has spoken nationally and internationally on lipids, atherosclerosis, and inflammation. Dr. Ballantyne's research interests include the pathophysiology of atherosclerosis, with an emphasis on monocyte activation and adhesion. His clinical interests include preventive cardiology, lipids, metabolic syndrome, atherosclerosis, genetics, and coronary artery disease.

	Wolfgang Koenig, MD, FRCP, FESC, FACC, FAHA Professor of Medicine/Cardiology Department of Internal Medicine II Cardiology University of Ulm Medical Center Ulm, Germany Dr. Koenig is a Professor of Medicine/Cardiology at the University of Ulm, Germany. He graduated from the Ludwig-Maximilians University in Munich and received his MD from the Rupprecht-Karls University in Heidelberg. He is a Board Certified internist and cardiologist with special interest in interventional cardiology. He is the Director of the Cardiac Catheterization Laboratories, Department of Internal Medicine II - Cardiology at the University of Ulm Medical Center and is the Director of the Hypertension and Heart Failure Clinics and the Preventive Cardiology Programme. Dr. Koenig's research interests involve the molecular basis of atherothrombogenesis with particular interest in the interrelations between hemostasis, inflammation, infection and atherothrombotic complications / type-2 diabetes, the clinical pharmacology of cardiovascular active compounds, and the clinical epidemiology of cardiovascular disorders. Dr. Koenig has published more than 180 research papers in journals including Nature, The Lancet, Circulation, British Medical Journal, Arteriosclerosis, Thrombosis & Vascular Biology, Atherosclerosis, and the European Heart Journal. From March to June 1999, he served as a Visiting Professor at the Department of Pharmacology, University of Pennsylvania, School of Medicine, Philadelphia, USA.

	Paul M Ridker, MD, MPH, FACC, FAHA Eugene Braunwald Professor of Medicine, Harvard Medical School Director, Center for Cardiovascular Disease Prevention Divisions of Cardiovascular Diseases and Preventive Medicine Brigham and Women's Hospital Boston, Massachusetts Dr. Ridker is the Eugene Braunwald Professor of Medicine at the Harvard Medical School and directs the Center for Cardiovascular Disease Prevention, a translational research unit at the Brigham and Women's Hospital in Boston which focuses on the molecular and genetic epidemiology of cardiovascular diseases. As a graduate of Brown University, the Harvard Medical School, and the Harvard School of Public Health, Dr. Ridker's primary research brings together classical tools of large-scale, population based epidemiology with emerging genetic and molecular techniques designed to improve our ability to predict and prevent thrombotic occlusion. Particular areas of interest involve molecular and genetic determinants of hemostasis, thrombosis, and inflammation with a focus on "predictive medicine", early disease diagnosis, and the underlying causes and prevention of acute coronary syndromes. Dr. Ridker's research efforts are supported by multiple RO1 research grants from the National Heart, Lung, and Blood Institute (NHLBI) as well a Distinguished Clinical Scientist Award from the Doris Duke Charitable Foundation. Dr. Ridker is also the Principal Investigator of PREVENT, an NHLBI-funded multi-center clinical trial of thrombosis prevention among individuals with and without genetic predispositions to hypercoagulability. Dr. Ridker additionally directs an NHLBI-funded institutional National Research Service Award (training grant) in cardiovascular epidemiology, and Co-Directs the Leducq Center for Cardiovascular Research at the Brigham and Women's Hospital and Harvard Medical School. Dr. Ridker has been the recipient of both a Clinician Scientist Award (1992-1997) and an Established Investigator Award (1997-2002) from the American Heart Association. A frequent invited lecturer at national and international conferences, Dr. Ridker lists among his honors elected membership into the American Society for Clinical Investigation (ASCI), the American Epidemiological Society (AES), and the American Association of Physicians (AAP). Citing his pioneering work on inflammation, C-reactive protein (CRP), and atherothrombosis, Time Magazine honored Dr. Ridker as one of America's Ten Best Researchers in Science and Medicine in 2001. In 2003, Dr. Ridker's work on inflammation and CRP lead to the first set of federal guidelines advocating CRP evaluation as a new method for cardiovascular disease detection. Also in 2003, Dr. Ridker was named as a Reynolds Investigator and as Co-Director of the Reynolds Center for Cardiovascular Research at the Harvard Medical School. Dr. Ridker is the author of over 190 original reports, 90 reviews and book chapters, and 3 textbooks related to cardiovascular medicine. Dr. Ridker serves on the editorial board of several major journals and is a Consulting Editor for Circulation. Dr. Ridker is listed as a co-inventor on several patents filed by the Brigham and Women's Hospital that relate to the use of inflammatory biomarkers in cardiovascular disease.

	James D. Katz, MD, FACP, FACR Associate Professor of Medicine Director, Division of Rheumatology The George Washington University Washington, DC James D. Katz, MD is associate professor of medicine and director of the division of rheumatology at The George Washington University, in Washington, DC. Dr. Katz also serves as the Director of the GWU Center for the Study of Myositis. He is the immediate past program director for the rheumatology fellowship-training program. Dr Katz received his undergraduate degree from Oberlin College and his medical degree from Case Western Reserve University, Cleveland, Ohio. He served his medicine internship and residency at the Western Pennsylvania Hospital in Pittsburgh, Pennsylvania. He went on to complete his rheumatology fellowship training at the University of Connecticut. Dr Katz is a diplomate in both internal medicine and in rheumatology. He has been honored both as Faculty Member of the Year by The George Washington University Department of Medicine and as visiting professor to the Columbia University Stroud Center for Study of Quality of Life. Dr. Katz has been listed in the Consumers Guide to Top Doctors by the Center for the Study of Services, Washington, DC and received The Arnold P. Gold Foundation Leonard Tow Humanism in Medicine Award. Dr Katz’s research interests, lectures, and publications have focused on crystal-induced arthropathies, CR-1-cytoskeletal interactions in neutrophils, gender-bias in medicine, and systemic lupus erythematosus. He is a fellow of the American College of Rheumatology and a fellow of the American College of Physicians.

	Ishwarlal Jialal, MD, PhD Robert E. Stowell Endowed Chair in Experimental Pathology Director of the Laboratory for Atherosclerosis and Metabolic Research Professor of Internal Medicine (Endocrinology, Clinical Nutrition and Vascular Medicine) University of California, Davis Medical Center Davis, CA Dr. Ishwarlal Jialal graduated with the equivalent of an MD, PhD from the University of Natal Medical School, Natal, South Africa, and thereafter undertook fellowships at the Joslin Diabetes Center, Harvard Medical School, and in the Division of Endocrinology, Metabolism and Nutrition at the University of Washington in Seattle. He then joined the faculty of the University of Texas Southwestern Medical Center at Dallas in 1988 as Assistant Professor and became Professor of Internal Medicine and Pathology with tenure in 1997. He was Director of the Division of Clinical Biochemistry and Human Metabolism and was the first hold of the C. Vincent Prothro Chair in Human Nutrition Research. He is presently the Robert E. Stowell Endowed Chair in Experimental Pathology, Director of the Laboratory for Atherosclerosis and Metabolic Research, and Professor of Internal Medicine, Division of Endocrinology, Clinical Nutrition and Vascular Medicine, at the University of California, Davis, Medical Center. To date, he has published over 360 original papers and invited reviews in the areas of diabetes, atherosclerosis, lipid metabolism, nutrition and vascular biology. He has received numerous awards for his research and has served on Editorial Boards of numerous journals including the American Journal of Clinical Nutrition, Journal of Molecular and Cellular Cardiology, Journal of Diabetes and Its Complications, and Atherosclerosis. Currently, Dr. Jialal serves as Section Editor of AJCP for Clinical Chemistry and Editor-in-Chief of Metabolic Syndrome & Related Disorders. His major research interest is in the role of oxidative stress and inflammation in atherosclerosis, understanding the cellular dysfunction and the role of inflammation in metabolic syndrome, and understanding the pathobiology of diabetic vasculopathies. He also has a long standing interest in hyperlipidemia and diabetes. His research has been funded over the years by the National Institutes of Health (NIH), American Diabetes Association, Juvenile Diabetes Research Foundation, and American Heart Association. He serves on the Grant Review Panels of the ADA and JDRF, as well as the National Institutes of Health including the Mentored Clinical Scientist Development Award Grant Review Panel for the K08 awards study section, Research Scientist Development KO1 awards, and other Special Emphasis Panels for the National Heart, Lung and Blood Institute. Dr. Jialal has received numerous awards for his work including the AHA Young Investigator Award; the VERIS Award for Nutrition Research; the Centrum Center Science for Nutrition Award, American Society of Nutritional Sciences; the International Hermes Prize for Vitamin Research; the Bennie Zak Award for Outstanding Research, Lipids and Lipoproteins Division, AACC; the Grace Goldsmith Award from the American College of Nutrition; the NIH Mid-Career Investigator Award in Patient Oriented Research, the Distinguished Scientist Award from the National Academy of Clinical Biochemistry, Recipient of the Outstanding Contributions to Clinical Chemistry in a Selected Area of Research Award of the American Association for Clinical Chemistry, the Linus Pauling Award, American College for Advancement in Medicine; Philip Levine Award, American Society of Clinical Pathology, Cooper Award, Lipoprotein and Vascular Diseases Division, AACC, Joliff Award, Division of Clinical and Diagnostic Immunology, AACC and Elected Member in Recognition of Outstanding Contributions to Medicine, Western Association of Physicians.

	Carlo Mainardi, MD, MBA, FACP, FACR Professor of Clinical Medicine Mt. Sinai School of Medicine New York, New York Vice President for Medical Affairs Newark Beth Israel Medical Center Newark, NJ Dr. Carlo Mainardi, the Chief of Rheumatology at Newark Beth Israel Medical Center has served as the VP for Medical Affairs and was the Chairman of Medicine at Newark Beth Israel Medical Center for more than 8 years. He is a graduate of UMDNJ. He has been the Chief of Rheumatology at UMDNJ-Robert Wood Johnson, the Chief of Medicine at the VA Medical Center in Memphis, TN, Interim Chairman of Medicine at the University of Tennessee, Memphis and was the founding Medical Director of Memphis Managed Care, Company. He has had a distinguished career in rheumatology research in the degradation of extracellular matrix in inflammation. He has served on the Research Committees of the National Arthritis Foundation and the American College of Rheumatology and as Chairman of a standing NIH Study Section. He was the founding CEO of the Physician/Hospital Organization at the University of Maryland Medical System and was Director of the Senior Health Program at the University of Maryland. He received a Masters of Business Administration from the Sellinger School at Loyola University in 1998. A rheumatologist, Dr. Mainardi has been the Chairman of the Governor’s Advisory Council on Arthritis (NJ) and is on the Board of Directors of the New Jersey Chapter of the Arthritis Foundation. Dr. Mainardi is a Fellow of the American College of Physicians, a Fellow of the American College of Rheumatology and a member of the American Society for Clinical Investigation.

CRPhealth.com is owned by E-MedHosting.com Inc. Last update: 2013-05-11

Disclaimer | Sponsors' Disclaimer | Help / Contact us

USER ACKNOWLEDGES AND AGREES THAT ALL DECISIONS MADE WITH THE ASSISTANCE OR USE OF THE SOFTWARE AND/OR THE WEBSITE AND/OR BASED ON THEIR CONTENT WILL BE EXCLUSIVELY THE RESPONSIBILITY OF THE USER.

CRPHEALTH.COM ::: C-REACTIVE PROTEIN (CRP), HS-CRP